Study Identifies Germline Variants Linked to Yescarta CAR-T Toxicity and Expansion

Jul 24, 2026

A genomic study of over 200 lymphoma patients reveals that inherited genetic variants significantly influence the safety and efficacy of CAR-T cell therapy. Researchers identified that silencing mutations in the STXBP2 gene trigger severe inflammation and toxicity, while variants in the ADAMTSL3 gene offer protection. Additionally, PTPN22 gene variants correlate with enhanced CAR-T cell expansion. These findings could guide the selection of optimal cell donors and the engineering of safer, more robust cellular immunotherapies.

Inherited genetic variants influence

▪The underlying germline genetics of a patient act as a major, intrinsic determinant of both CAR-T cell expansion and clinical toxicity.
▪A patient's inherited genetic makeup can influence whether they benefit from CAR-T cell therapy or experience treatment-related toxicity.

CAR-T therapy toxicity risk

▪CAR-T cell therapy can cause serious side effects, including cytokine release syndrome and toxicities that vary among patients.
▪A second drop in blood counts, or cytopenia, occurs in more than 50% of patients about 3 to 6 weeks following CAR-T therapy, often driven by inflammation.

STXBP2 gene silencing effects

▪Inherited genetic variants that silence the STXBP2 gene correlate with an increased risk of experiencing toxicity related to CAR-T cell therapy.
▪Donor T cells engineered to lack the STXBP2 gene or express STXBP2-silencing variants trigger inflammation.
▪Six patients in the Zuma-1 clinical trial had mutations that knocked out STXBP2 function, and all six experienced toxicity after treatment.

ADAMTSL3 protective variants

▪Inherited variants in the ADAMTSL3 gene correlate with protection from CAR-T treatment-related toxicity.

PTPN22 CAR-T cell expansion

▪Variants in the PTPN22 gene are strongly associated with enhanced CAR-T cell expansion, which correlates with effective therapy.
▪Intentional knockouts or knockdowns of the PTPN22 gene could potentially be incorporated into manufacturing protocols to enhance cell expansion and reduce required doses.

Genome sequencing study methodology

▪The genomic analysis of CAR-T therapy patients was limited by focusing almost exclusively on patients of European descent.
▪Researchers sequenced the entire genomes of more than 200 patients with aggressive lymphoma from two major clinical trials of CAR-T cell therapy.